Det är svårt att leva med hATTR(1,2)

Att leva med hATTR

Det är svårt att leva med hATTR(1,2)

Det är svårt att leva med hATTR^1,2

Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(suppl 7):S107–S112.
Amyloidosis Foundation. Understanding the patient voice in hereditary transthyretin-mediated amyloidosis (ATTR amyloidosis). Available at: https://www.amyloidosissupport.org/support_groups/fam_isabell_attr.pdf. Accessed April 2020.
Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidosis: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory agency approved drug. J Mol Biol. 2012;421(2-3):185-203.
Ando Y et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
Gertz M, Adams D et al., BMC Fam Pract. 2020 Sep 23;21(1):198.
Adams D, Ando Y et al., J Neurol. 2021 Jun;268(6):2109-212.
Monteiro C, Mesgazardeh JS et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. 2019 Jun 20;4(12):e126526
Tegsedi produktresumé. November 30, 2023. fass.se